NCT06955598View on ClinicalTrials.gov

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 24, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

SHR-2173

SHR-2173

Trial Locations (1)

200000

Renji Hospital affiliated to Shanghai Jiaotong, Shanghai

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06955598 - A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter